The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Clinical comparative study of ticagrelor and clopidogrel in treatment of acute coronary syndrome with a history of ischemic stroke
Author(s): 
Pages: 449-453
Year: Issue:  4
Journal: World Phytomedicines

Keyword:  Ticagrelor TabletsClopidogrel Hydrogen Sulfate Tabletsischemic strokeacute coronarysyndromeIL-6hs-CRP;
Abstract: Objective To compare the clinical curative and safety of Ticagrelor Tablets and Clopidogrel Hydrogen Sulfate Tablets in treatment of acute coronary syndrome with a history of ischemic stroke. Methods Patients(66 cases) with acute coronary syndrome with a history of ischemic stroke in Shanghai Putuo District Central Hospital from May 2014 to March 2015 were randomly divided into control(31 cases) and treatment(35 cases) groups. All patients were given the conventional treatment without PCI treatment. Patients in the control group were po administrated with Clopidogrel Hydrogen Sulfate Tablets at loading dose of 300 mg, then with maintenance dose 75 mg, once daily. The patients in the treatment group were po administered with Ticagrelor Tablets, at loading dose of 180 mg, then with maintenance dose 90 mg, twice daily. The patients in two groups were treated for 30 d. After treatment, the efficacy was evaluated. The cardiovascular adverse events(MACCE), incidence of bleeding events, and adverse drug reactions were compared, and levels of IL-6 and hs-CRP were determined at 7 and 30 d. Results After treatment, the efficacies in the control and treatment groups were 90.3% and 97.1%, respectively, and there were differences between two groups(P < 0.05). After treatment for 7 and 30 d, there were significant difference in MACCE and incidence of bleeding events between two groups(P < 0.05), but there were no significant difference in adverse drug reactions between two groups. After treatment for 7 and 30 d, the levels of IL-6 and hs-CRP in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusions Ticagrelor Tablets has clinical curative effect in treatment of acute coronary syndrome with a history of ischemic stroke, can significantly reduce the incidence of MACCE, prohibit the levels of inflammatory cytokines, which be superior to Clopidogrel Hydrogen Sulfate Tablets and has a certain clinical application value.
Related Articles
No related articles found